MOLECULAR MECHANISMS DISTINGUISH FOLLICULAR ADENOMA/FOLLICULAR CARCINOMA

区分滤泡性腺瘤/滤泡性癌的分子机制

• 批准号: 6218204
• 负责人: MARTHA A ZEIGER
• 金额: $ 0.23万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6218204
• 关键词: adenoma; biomarker; carcinoma; chromosome aberrations; clinical research; cytology; diagnosis design /evaluation; diagnosis quality /standard; enzyme activity; human subject; loss of heterozygosity; molecular oncology; neoplasm /cancer diagnosis; nucleic acid repetitive sequence; telomerase; thyroid neoplasm

Over 28,000 thyroidectomies are performed in the United States annually for suspected malignancy. However, up to 18,000 of these are benign on permanent histology. This phenomenon is due to the fact that fine needle aspirations (FNA) of the thyroid that are suspicious for malignancy ultimately turn out to represent a benign process in 60% of cases. Because of this phenomenon we chose to examine follicular neoplasms of the thyroid for molecular markers that would distinguish a follicular adenoma from a carcinoma.

在美国，每年有超过28，000例甲状腺切除术用于疑似恶性肿瘤。 然而，其中多达18，000例在永久组织学上是良性的。 这种现象是由于甲状腺细针穿刺（FNA）怀疑恶性肿瘤，最终在60%的病例中表现为良性过程。 由于这种现象，我们选择检查甲状腺滤泡性肿瘤的分子标记物，以区分滤泡性腺瘤和癌。